Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04718584
Other study ID # LDP-II-01
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date September 11, 2020
Est. completion date November 2023

Study information

Verified date January 2021
Source Dragonboat Biopharmaceutical Company Limited
Contact Wenli Ji
Phone #86#021-50276381-637
Email wenli.ji@dragonboatbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-arm,open, multicenter, phase II clinical study of the efficacy and safety of human anti-PD-L1 monoclonal antibody Injection (LDP) in the treatment of urinary and male genital tumors.


Description:

This trial is a single arm, open, multicenter, Ⅱ period clinical research. Three cohorts were included, 127 subjects were enrolled (Cohort 1: about 60 subjects with surgically suitable muscular-invasive bladder cancer; Cohort 2: about 40 subjects with advanced Non-clear Cell Renal Carcinoma; Cohort 3: about 27 subjects with advanced penile carcinoma. After confirmation of inclusion, intravenous infusion of 10mg/kg human anti-PD-L1 monoclonal antibody injection (LDP) was given. The initial efficacy and safety of drugs in different tumor species in the cohort above will be observed.


Recruitment information / eligibility

Status Recruiting
Enrollment 127
Est. completion date November 2023
Est. primary completion date November 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age = 18 (inclusive), =18 (inclusive) 2. Patients with muscular-infiltrating bladder cancer suitable for surgery; advanced opaque cell renal carcinoma; advanced penile carcinoma 3. The estimated survival time is more than 3 months. 4. At least one assessable tumor lesion according to RECIST1.1 (in cohort 1, evaluate lesion is accept); 5. ECOG physical strength score 0-1; 6. Enough organ function: Blood routine (no blood transfusion or colony stimulating factor (G-CSF) treatment within 14 days):ANC=1.5×109 / L, PLT=75×109 / L, Hb=80g/L; Liver function: TBIL=1.5×ULN, ALT=2.5×ULN, AST=2.5×ULN (ALT,AST=5×ULN for liver metastasis patients); Renal function: Cr = 1.5 × ULN, and creatinine clearance > 50 ml /min(according to Croft Gault formula) ; Coagulation function: APTT= 1.5 ×ULN, PT = 1.5 × ULN, INR = 1.5 × ULN; 7. Eligible patients (male and female) with fertility must agree to use reliable methods of contraception (hormone or barrier or abstinence) during the trial period and at least 6 months after the last dose; The blood or urine pregnancy test within 7 day before being selected must be negative for the female patients of childbearing age; 8. Subjects must give informed consent to this study before the study, and voluntarily sign a written informed consent; Exclusion Criteria: 1. Received radiotherapy, chemotherapy, targeted therapy, endocrine therapy or immunotherapy within 4 weeks before the first administration, or other unlisted clinical trial drug therapy (mitomycin and nitrosourea are 6 weeks from the last administration, oral fluorouracil drugs such as Tegiol and Capecitabine are at least 2 weeks from the last administration, small molecule targeted drugs are at least 2 weeks or at least interval 5 half-life (Subject to the longer time) from the last administration, and traditional Chinese medicine with antitumor indications are at least 2 weeks from the last administration. 2. Major organ surgery (excluding puncture biopsy) or significant trauma occurred within 4 weeks prior to the first administration. 3. The adverse effects of previous antitumor therapy have not recovered to CTCAE 5.0 =grade1 (except for alopecia) 4. Patients with clinical symptoms of brain metastases, spinal cord compression, cancerous meningitis, or other evidence of uncontrolled brain or spinal cord metastases are not suitable for inclusion as judged by the investigator 5. Patients who had previously received PD-1 or PD-L1 inhibitors; 6. Immunorelated adverse events = Grade 3 were observed in previous immunotherapy except for PD-1 or PD-L1 inhibitors; 7. Patients have any active autoimmune diseases or a history of autoimmune diseases (e.g., but not limited to: systemic lupus erythematosus, autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, vitiligo, etc.); Complete remission of asthma in childhood can be included if in adults without any intervention;Asthma patients requiring bronchodilators for medical intervention were excluded); 8. Patients who received systemic corticosteroid (prednisone > 10mg/ day or equivalent) or other immunosuppressive therapy within 14 days prior to initial dosing; Exceptions include: topical, ocular, intraarticular, intranasal, and inhaled corticosteroids;Short-term use of corticosteroids for preventive treatment, such as before the use of contrast agents; 9. Malignancies that were active within the last 2 years prior to initial administration (except for the tumors targeted in this study); 10. Uncontrolled active hepatitis B (HBsAg positive with HBV DNA copy number > 103/ mL or HBV DNA titer >200 IU/ mL); Hepatitis C; 11. Syphilis infection (syphilis antibody positive) and HIV positive patients. 12. A history of serious cardiovascular disease, including ventricular arrhythmias requiring clinical intervention;Acute coronary syndrome, congestive heart failure, stroke, or other grade 3 or higher cardiovascular events within 6 months;New York Heart Association (NYHA) cardiac function grade =II or left ventricular ejection fraction (LVEF) < 50%;Patients with clinically uncontrolled hypertension who are not suitable for the trial as determined by the investigator; 13. Patients with a history of other serious systemic diseases who have been determined by the investigator to be unsuitable for participation in clinical trials; 14. Known alcohol or drug dependence; 15. Mental disorder or poor compliance; 16. Women who are pregnant or lactating; 17. Have received live attenuated vaccine within 4 weeks before the first administration or scheduled to receive during the study period. 18. The Investigator considers that the subject is unsuitable to participate in this study because of any clinical or laboratory test abnormalities or other reasons.

Study Design


Intervention

Drug:
Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)
All participants will receive treatment with LDP 10mg/kg once every two weeks, every 2 weeks will be a cycle. In Cort 1, surgical treatment will be performed within 2 weeks after the end of 3 cycles of treatment.

Locations

Country Name City State
China Dragonboat Biopharmaceutical,Co.,Ltd Shanghai Shanghai

Sponsors (2)

Lead Sponsor Collaborator
Dragonboat Biopharmaceutical Company Limited Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Case complete response (pCR) The pCR is defined as the case complete response in Cohort 1 (muscular-infiltrating bladder cancer suitable for surgery) At the end of the cycle 3 of treatment (each cycle is 14 days).
Primary Objective response rate (ORR) The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1 in Cohort 2 (Non-clear Cell Renal cell Carcinoma) and Cohort 3 (advanced penile carcinoma) From first dose of LDP through 21 days after last dose of LDP up to 2 years.
Secondary Recurrence-free survival (RFS) Recurrence-free survival (RFS) is defined as the time from the start of surgery to the earliest evidence of recurrence. One year after surgery or disease progression or intolerant toxicity, up to 2 years.
Secondary Progression-free survival (PFS) Progression-free survival (PFS) is defined as the time elapsed from the day the study drug was first administered until the first imaging assessment of disease progression (PD) or death from any cause. From first dose of LDP, up to 2 years.
Secondary Disease control rate (DCR) Disease control rate (DCR) is defined as the proportion of the optimal time response of CR, PR, disease stable (SD) (i.e. CR+PR+SD) between initiation of the trial drug and withdrawal from the trial, as assessed according to RECIST1.1 criteria. From first dose of LDP, up to 2 years.
Secondary Duration of response (DOR) The duration of response (DOR) is defined as the time from the beginning of the first tumor assessment as PR or CR to the first assessment as PD or death from any cause. From first dose of LDP, up to 2 years.
Secondary Overall survival (OS) Overall survival (OS) is defined as the time between the date of first use of the study drug and death from any cause. From first dose of LDP, up to 2 years.
Secondary Incidence of adverse events Adverse events (AEs) refer to all adverse medical events that occur when subjects sign the informed consent, which may be manifested as symptoms, signs, diseases or abnormal laboratory tests, but not necessarily causally related to the investigational drug. From first dose of LDP through 30 days after last dose of LDP, up to 5 months.
Secondary Incidence of abnormal vital signs Vital signs (including temperature, respiration, heart rate and blood pressure) can be measured. The time window for each vital sign measurement is ±10 minutes. From first dose of LDP through 30 days after last dose of LDP, up to 5 months.
Secondary Incidence of abnormal ECOG scores ECOG physical strength rating is based on ECOG physical strength rating criteria. From first dose of LDP through 30 days after last dose of LDP, up to 5 months.
Secondary Incidence of abnormal laboratory tests results Descriptive analysis of laboratory results for safety analysis. From first dose of LDP through 30 days after last dose of LDP, up to 5 months.
Secondary Incidence of abnormal physical examinations Descriptive analysis of physical examination for safety analysis. From first dose of LDP through 30 days after last dose of LDP, up to 5 months.
Secondary anti-drug antibody (ADA) Anti-drug antibody (ADA) is tested for immunogenicity assessment , titer and neutralizing antibody analysis were performed when ADA was positive, and immunocomplex (CIC) and complement analysis were performed. In Cohort 1: before administration ,before surgery; In Cohort 2, 3: before administration, up to 4 months.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06034015 - A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers Phase 1
Recruiting NCT04235764 - En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device
Completed NCT02371447 - VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer Phase 1/Phase 2
Recruiting NCT04081246 - Transurethral Modified En Bloc Resection For Large Bladder Tumours. N/A
Recruiting NCT06059547 - Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer Phase 2
Terminated NCT04779489 - Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer N/A
Not yet recruiting NCT04493489 - Propranolol Adjuvant Treatment of Bladder Cancer Phase 2
Completed NCT03520231 - Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases Phase 2
Recruiting NCT04537221 - Nordic Cystectomy Study III - Transfusion
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Completed NCT04487457 - Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of Chemotherapy
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT05562791 - A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer Phase 1
Completed NCT00199849 - NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine Phase 1
Completed NCT02781428 - To Detect the Sensitivity of the UroMark Assay
Recruiting NCT04738630 - Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Phase 2
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2
Active, not recruiting NCT03978624 - Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer Phase 2
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A